Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia - Scorecard - MDSpire

Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia

  • By

  • Ondřej Fiala

  • Michaela Tkadlecová

  • Tomas Buchler

  • Jindřich Kopecký

  • Zuzana Tomčová

  • Michal Vočka

  • Zuzana Syčová-Milá

  • Hana Študentová

  • Martin Matějů

  • Alexander Savka

  • Eva Šlachtová

  • Peter Priester

  • Jan Králíček

  • Martina Spisarová

  • Anežka Zemánková

  • Radka Lohynská

  • Lucie Grmelová

  • Jana Obertová

  • Petr Stránský

  • Bohuslav Melichar

  • Alexandr Poprach

  • Patrik Palacka

  • June 30, 2026

  • 0 min

Share

Clinical Scorecard: Nivolumab for Metastatic Renal Cell Carcinoma After Prior Treatment: Insights from Real-World Data in the Czech Republic and Slovakia

At a Glance

CategoryDetail
ConditionMetastatic Renal Cell Carcinoma (mRCC)
Key MechanismsNivolumab is an immune checkpoint inhibitor that enhances anti-tumor immune responses.
Target PopulationAdults with histologically confirmed mRCC treated in second or later line after prior therapy.
Care SettingReal-world clinical practice across cancer centers in the Czech Republic and Slovakia.

Key Highlights

  • Median overall survival (OS) was 24.2 months.
  • Median progression-free survival (PFS) was 8.6 months.
  • Objective response rate (ORR) was 28.8%; disease control rate (DCR) was 61.2%.
  • Grade 3/4 adverse events occurred in 11.4% of patients.
  • Higher baseline NLR and PLR were associated with inferior survival.

Guideline-Based Recommendations

Diagnosis

  • Histologically confirmed metastatic renal cell carcinoma.

Management

  • Nivolumab monotherapy is indicated for previously treated patients in second or later lines.

Monitoring & Follow-up

  • Regular follow-up visits every two to four weeks and imaging every three to four months.

Risks

  • Monitor for grade 3/4 adverse events and assess treatment-related toxicity.

Patient & Prescribing Data

501 patients with mRCC treated with nivolumab.

Nivolumab demonstrated consistent clinical activity and manageable toxicity in real-world settings.

Clinical Best Practices

  • Utilize baseline inflammatory indices (NLR, PLR) for prognostic assessment.
  • Follow local clinical practice guidelines for nivolumab administration.

Related Resources & Content

Original Source(s)

Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia

  • by Ondřej Fiala, Michaela Tkadlecová, Tomas Buchler, Jindřich Kopecký, Zuzana Tomčová, Michal Vočka, Zuzana Syčová-Milá, Hana Študentová, Martin Matějů, Alexander Savka, Eva Šlachtová, Peter Priester, Jan Králíček, Martina Spisarová, Anežka Zemánková, Radka Lohynská, Lucie Grmelová, Jana Obertová, Petr Stránský, Bohuslav Melichar, Alexandr Poprach, Patrik Palacka

  • June 30, 2026

Related Content